Biotechnology

Omega Therapeutics

Omega Therapeutics released FY2024 Cumulative Q3 Earnings on November 14, 2024 (EST), with Revenue of 7.106M USD and EPS of -0.9631

Omega Therapeutics released FY2024 Q3 earnings on November 14 (EST), actual revenue 2.612 MUSD (forecast 1.342 MUSD), actual EPS -0.2981 USD (forecast -0.3 USD)

HC Wainwright reiterates 'buy' rating on Omega Therapeutics (OMGA)

Omega Therapeutics Inc: Raymond James initiates coverage with an outperform rating; target price $12.

Luminar Tech

Novabay Pharmac

Mint Incorporation

Autozi Internet Tech Global

GD Culture

Impact BioMedical

Tradr 2X Long FLY Daily ETF

Leverage Shares 2X Long CRWV Daily ETF

T-REX 2X Long CRWV Daily Target ETF

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

阿里拉姆制藥

Argenx

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap